BioAdaptives (OTC: BDPT) has detailed the scientific strategy behind its Xcellara cellular wellness platform ahead of the planned August 1 commercial launch of XcellaraHeart. The platform combines a stem/progenitor cell mobilization base, supported by a human randomized controlled trial showing an average 268.8% increase in circulating stem/progenitor-type cells, with tissue-specific ingredients designed to support the body’s natural signaling pathways and direct those cells to targeted areas.
XcellaraHeart, the platform’s first commercial application, pairs the Xcellara base with Tanshinone IIA, a Danshen-derived compound studied for its role in cardiovascular SDF-1α/CXCR4 signaling. BioAdaptives plans to expand the platform with additional formulas targeting wellness categories including joint mobility, skin health, cognitive wellness, and metabolic resilience using the same supply-and-direction development model.
The company’s Xcellara base formula is the only dietary supplement with a human randomized, double-blind, placebo-controlled clinical trial demonstrating a 268.8% increase in circulating hematopoietic stem and progenitor cells at four weeks with zero adverse effects on more than twenty blood parameters. The complete scientific evidence dossier for the XcellaraHeart formulation will be available at products.xcellara.com/science. The dossier separates what has been demonstrated in BioAdaptives’ human clinical research on the Xcellara base from published research on Tanshinone IIA and from the company’s product-development rationale for combining the two.
BioAdaptives is the developer of the Xcellara line of stem cell mobilization and tissue-homing supplements. The Xcellara product line includes seven targeted formulas combining the clinically proven mobilization base with tissue-specific signaling ingredients for cardiac, joint, neural, dermal, longevity, and stress-resilience applications. For more information, visit products.xcellara.com.
This announcement is significant as it provides insight into the company's strategy for expanding its product line beyond the initial cardiac-focused formula, potentially addressing multiple wellness categories. The clinical trial data supporting the base formula adds credibility to the platform approach. However, the company has not yet disclosed results from human trials of the combined formulations, and the dossier separates proven results from published research and development rationale.
